1 / 8

International Assessment Of Research and Development in Rapid Vaccine Manufacturing

International Assessment Of Research and Development in Rapid Vaccine Manufacturing. a vision for the future. Efficient production Flexible Modular Agile Economic viability Return on investment Drives innovation Efficacious vaccines Increased response rate Reduced adverse events.

denis
Download Presentation

International Assessment Of Research and Development in Rapid Vaccine Manufacturing

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. International Assessment Of Research and Developmentin Rapid Vaccine Manufacturing

  2. a vision for the future • Efficient production • Flexible • Modular • Agile • Economic viability • Return on investment • Drives innovation • Efficacious vaccines • Increased response rate • Reduced adverse events

  3. technology and engineering as a driver • US status • Discovery based innovation • Technology based innovation • Discovery through delivery • Traditional vaccines • Needed vaccines

  4. disease emergence as a driver • What if’s • Pandemic flu • SARS • A new WNV or arbovirus • An engineered microbe • A really old pathogen coming out of melting ice flows

  5. traditional vaccines • Existing threat • Base line prevalence • Seasonal expectations • Defined at risk populations • Known morbidity and mortality

  6. a new paradigm • Emergent threat • Unknown pathogen (or at least unidentified) • Unknown source and natural history • Unknown routes of transmission • Unknown vectors • Unknown pathology • Unknown immune response • Unknown risk of transmission • Everyone is at risk • Immuno-compromised are more at risk • No effective therapy • Unknown morbidity and mortality

  7. needs based approach • Assessment of existing assets • Identification of current trends • Identification of emerging critical science, technologies and processes • Stimulation of new concepts and approaches • Strategic investment in bottlenecks • Strategic investment in new technologies and science

  8. the WTEC panel Chairman: Joe Bielitzki, University of Central Florida, Chief Science Advisor, Inventure Holdings, formerly DARPA Terrance Leighton, Children’s Hospital Oakland Research Institute (CHORI) Glen Barber, University of Miami Medical School Stephen Drew, President, Drew Solutions Sheldon Jacobson, University of Illinois, Urbana Cyril Gay, U.S. Department of Agriculture Mary Ritchey, Ritchey Associates, Inc.

More Related